On The Pen: The Weekly Dose Podcast
1) FDA CRACKDOWN on Compounded GLP-1s | Novo’s Gut Hack & Lilly’s One-Shot Cure
🚨 FDA cracks down on compounded GLP-1 medications, raising questions about the future safety, quality, supply, and cost. In this episode of On The Pen Live, we break down what the FDA’s new “green li...Show More
2) Is Wegovy Better Than Zepbound? Plus the First Obesity GLP-1 Generic is Here!
This episode of On The Pen: The Weekly Dose Podcast breaks down four major stories in obesity medicine: the FDA’s approval of Teva’s so-called “generic” Saxenda at a sky-high price, Wegovy’s accelerat...Show More
3) Zepbound Compound Lawsuit Update: Eli Lilly Vs Mochi
Sabina from GLPwinner.com who was in attendance yesterday, sits down in an exclusive OTP interview to discuss yesterday’s s hearing between Eli Lilly and Mochi health.
4) Eli Lilly VS Mochi Update + Big Lilly Orforglipron Secret Revealed
5) Ozempic Price Cut + New Obesity Pill Data
In Today's live Podcast, Dave covers the latest breaking news in Obesity Medicine, including fresh data on an oral #GLP1 that we have been following for years from #VikingTherapeutics Learn more abo...Show More
6) GLP-1 Microdosing For Weight Loss: Noom CEO Explains Their New Program
GLP-1 microdosing is one of the hottest and most controversial topics in obesity medicine right now. Can lowering your dose instead of quitting completely help you keep the weight off? In this exclusi...Show More
7) Eli Lilly Earnings Call Recap: Stock Tanks on Weight Loss Pill Miss
Zepbound now leads two-thirds of the U.S. obesity market—and that’s just the beginning. In this video, we break down the biggest headlines from Eli Lilly’s latest earnings call, including: ✅ Over 1...Show More
8) Novo Nordisk Blames Compound Semaglutide on Slower Sales
Novo Nordisk Q2 2025 Earnings: What It Means for GLP-1s, Compounded Semaglutide, Amycretin & Obesity Treatment In this breakdown of Novo Nordisk’s Q2 2025 earnings call, I cover the biggest takeawa...Show More
9) No Compounded Retatrutide Says the FDA + Tons of GLP-1 News
This week Dave covers all the obesity medicine news that will empower you to have more informed conversations with your doctor. This week's topics include: FDA Statement on Non Branded GLP-1 Meds Li...Show More
10) LEAKED TRUMP DOCUMENT: Medicare to Cover Zepbound and Wegovy for Obesity
Breaking News Today from the Trump administration on the cost of GLP-1